Summit Therapeutics Inc. presented data from the Phase III HARMONi trial featuring ivonescimab at WCLC 2025.
The trial evaluated ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients.
Results show a positive trend in OS with a hazard ratio of 0.79 but did not reach statistical significance.
Positive Trend in OS
Ivonescimab plus chemotherapy demonstrated a positive trend in Overall Survival (OS) with a hazard ratio of 0.79.
Longer-Term Follow-Up
The longer-term follow-up of Western patients showed improving global OS trends with a nominal p-value of 0.0332.
Consistent Benefit Across Subgroups
Consistent benefit was observed across pre-defined subgroups in the analysis with longer-term follow-up.
- Analysis with longer-term follow-up of Western patients showed improved hazard ratios and nominal p-values.
- North American patients in the study demonstrated a median OS HR of 0.70 in the ivonescimab arm.
- The data presented at WCLC 2025 indicates potential clinical significance for ivonescimab in EGFR-mutated NSCLC patients.
The Phase III HARMONi trial data presented at WCLC 2025 provides valuable insights into the efficacy of ivonescimab in treating EGFR-mutated NSCLC patients. The results, although not statistically significant, show promising trends in overall survival.